anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: cosmetology. SUBSTANCE: the present innovation deals with cosmetic preparations, those for skin care, in particular. The suggested hygienic gel includes glycerol, perfumery composition, disinfectant and water. As disinfectant one should apply either polyguanidine compound or its synergistic mixture with quaternary ammonium compound, citric acid, cremaphor and trilon B sodium salt of ethylene diamintetracetic acid at certain ratio of components. As polyguanidine compound one should apply phosphate of poly-(4.9-dioxadodecane-1.12- guanidine), or citrate/formiate of polyhexamethylene guanidine, or gluconate/benzoate of polyhexamethylene guanidine, or chloride of polyhexamethylene guanidine; as quaternary ammonium compound one should apply dimethylbenzyldodecylammonium-sulfate, as polyethylene glycol compounds of [-CH 2 CH 2 O-] n H, class, where n=6-20, as vitamin constituent it is necessary to use either vitamin A or vitamin E, or provitamin B 5  or their mixture in equal portions. The present innovation provides decreased toxicity of suggested gel at improved dermatological action and prolonged effect. EFFECT: higher efficiency. 4 cl, 4 ex, 3 tbl
(1) Sepsis-related datasets GSE65682,GSE134347 and GSE134358 were downloaded from GEO database, and DEmRNA,DElncRNA and DEmiRNA were obtained by differential analysis. (2) Autophagy related genes (ARGs) were obtained from Human Autophagy Database, and ARGs in GSE65682 and GSE134347 were extracted. DEARGs were obtained by differential analysis, and GO and KEGG enrichment analysis were performed. (3) Sepsis-related genes were obtained by WGCNA analysis, and key DEARGs in sepsis were obtained by intersection with DEARGs, and then transcription factors and ceRNA regulatory network were analyzed. (4) Immune infiltration analysis was used to evaluate the distribution of immune cells in the blood of patients with sepsis, and its correlation with key DEARGs was further analyzed. (5) The diagnostic functions of key DEARGs were analyzed. (6) Peripheral blood samples from sepsis patients and healthy controls were collected and verified by RT-qPCR.
Prontosan, with the active substance PHMB, is recommended by 19 out of 21 regions in Sweden, for cleaning DFU. The DFU will be cleaned with PHMB twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.
Tuberculosis (TB) remains one of the important infectious diseases worldwide. Timely implementation of optimized anti-tuberculous therapy is still the mainstay to prevent further transmission of TB. However, hepatitis during anti-tuberculous treatment (HATT) has been an obstacle in managing TB patients, especially in those with viral hepatitis. A previous study revealed the risk of HATT is significantly higher in TB patients with high serum hepatitis B virus (HBV) DNA level than those with low HBV DNA level (39% vs. 11%), the latter cases have a similar risk of HATT as those without viral hepatitis (14%). Based on these findings, we thus hypothesize that the risk of HATT in TB patients with high baseline serum HBV DNA level can be reduced by concomitant use of anti-HBV agent. In this proposal, we will conduct a prospective randomized clinical study to assess the reduction of HATT risk by using entecavir in TB patients with high baseline serum HBV DNA level, and to evaluate the risk of other treatment-related adverse events in two hospitals. From January 2012 to June 2014, subjects with culture-confirmed TB and aged from 18 to 80 with high serum HBV viral load prior to anti-tuberculous treatment will be enrolled and randomized into either study or control group. High serum HBV viral load is defined as \>20,000 and \>2,000 IU/mL for HBeAg-positive and HBeAg-negative subjects, respectively. In addition to standard anti-tuberculous treatment, subjects in the study group will receive entecavir (BARACLUDE®) 0.5 mg per day during anti-tuberculous treatment and for 6 months after stopping anti-tuberculous treatment. Hemogram, liver function, renal function, and serum HBV viral load will be regularly monitored to detect the development of HATT and other adverse events. In this study, HATT is defined as fulfilling anyone of the following conditions: (1) increase in serum AST and/or ALT level of \>3 times upper limit of normal (ULN) with symptoms if baseline liver function is normal; (2) increase in serum AST and/or ALT level of \>5 times ULN without symptoms if baseline liver function is normal; (3) increase in serum AST and/or ALT level of \>2 times baseline if baseline liver function is abnormal; and (4) increase in serum total bilirubin level of \> 2.5 mg/dL.
Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Multiple Sclerosis pose substantial public health challenges. While genetics play a primary role, recent research emphasizes the impact of environmental factors, particularly diet and lifestyle. This study investigates the initiating effects of Omega (ω)- 3 and Omega (ω)- 6 fatty acids on neuroinflammation, potentially contributing to these diseases. Using BV-2 microglial cells, we explored the influence of different fatty acid compositions and ratios on cell viability, cytokine production, morphological changes, and lipid peroxidation. Notably, a 2/1 ω-6:ω-3 ratio led to decreased cell viability. Fatty acid compositions influenced cytokine secretion, with reduced TNF-α suggesting anti-inflammatory effects. IL-17 increased, while IL-4 and IL-10 decreased in the 15/1 ω-6:ω-3 ratio, indicating complex cytokine interactions. This study found that polyunsaturated fatty acids interventions induced microglial activation, altering cell morphology even without immunostimulants. These findings demonstrate the intricate nature of fatty acid interactions with microglial cells and their potential implications for neuroinflammation. Further research is needed to clarify mechanisms and their relevance to neurodegenerative diseases, informing possible therapeutic strategies.
Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
INTRODUCTION: Patients with chronic graft versus host disease (cGVHD) have low circulating regulatory T cells (Tregs). Interleukin-2(IL-2) is a growth factor for Tregs, and clinical trials have explored its use in cGVHD patients.
AREAS COVERED: Here we will discuss the biology of IL-2, its rationale for use and results of clinical trials in cGVHD. We also describe its mechanisms of action and alteration in gene expression in T-cell subsets after treatment with low dose IL-2 and photopheresis.
EXPERT OPINION: Clinical trials using Low dose IL-2 have been done at single centers in small patient series. The majority of the clinical responses seen with IL-2 in cGVHD are classified as partial responses and efficacy as a single agent is limited. Compared to currently approved oral therapies, it has to be administered subcutaneously and requires specialized processing for compounding and storage limiting its widespread use. Its use is associated with constitutional symptoms and local injection site reactions. Local reactions can be easily managed by supportive care practices like rotation of injection sites and premeditations, constitutional symptoms resolve with, dose reduction (25-50%) allowing for continued therapy. Additional studies are needed to define optimal combination strategies with approved agents. Longer acting formulations of IL-2 that require less frequent dosing may also improve patient compliance.
Diclofenac has analgesic, anti-inflammatory, and antipyretic properties.

The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.

Heparin sodium is included in the LICART formulation as an inactive ingredient. In one study in healthy human volunteers activated partial thromboplastin time (aPTT), a measure of coagulation, was unchanged following multiple LICART applications.
Crystalline ammonium penicillin salts are manufactured by reacting penicillin acids, dissolved in a water-immiscible organic solvent, with ammonia in the presence of one or more water-miscible aliphatic ketones (e.g. acetone or butanone).  The reaction is advantageously effected by passing in gaseous ammonia until the pH reaches about 5-9 (preferably about 7 in the case of relatively crude solutions).  In an example, a crude solution of penicillin salts is acidified with sulphuric acid to pH 2 and extracted with chloroform, the chloroform extract is dried and filtered, acetone is added and gaseous ammonia passed through the agitated solution until the pH is 7.8.  The precipitate is separated, washed with acetone and ether and dried, and may be recrystallized from a water-miscible organic solvent, e.g. acetone or butanone.  Specification 578,590 is referred to.
In recent years, there have been a growing number of individuals diagnosed with Autism Spectrum Disorders (ASD). As such, this increase has expanded the number of caregivers of children with ASD. Research has shown that having a child with an ASD is stressful for caregivers and their families. More specifically, prior research suggests that caregivers of children with ASD may find it difficult to maintain feelings of control and to cope with the overall physical and emotional demands of caring for their child. A previous study of caregivers of children with ASD found that caregivers felt a lack of personal control over aspects of their child s condition and also found it difficult to cope with various demands of caregiving. Furthermore, this study found that greater levels of perceived personal control and the use of problem-focused coping strategies were associated with caregivers adaptation to their child s condition. As such, the goal of our research is to conduct a feasibility study using a coping effectiveness training (CET) intervention designed to enhance perceived personal control (PPC) and coping efficacy in caregivers of children with ASD. There has been a growing interest in developing interventions targeted at constructs involved in the adaptation process. However, there have been few studies of interventions targeting predictors of adaptation such as PPC and coping efficacy. Research has shown that the CET intervention can enhance coping efficacy in several other populations. This intervention also incorporates appraisals of one s ability to change a particular situation. The conceptual framework for our study was adapted from Lazarus and Folkman s Transactional Model of Stress and Coping. A cross-sectional randomized treatment-control design is proposed to evaluate the use of a CET intervention intended to enhance PPC and coping efficacy. Caregivers of children with ASD will be recruited from support groups, autism resource centers, and four clinics. Participants randomized to the treatment group will be asked to complete baseline and follow-up surveys and two 1.5-hour individualized in-person sessions. Participants randomized to the control group will be asked to complete baseline and follow-up surveys and two 1.5-hour individualized in-person client-centered discussion sessions. The main outcome measures will be participation, reasons for withdrawal, participants experiences within the intervention setting and their experiences in applying the intervention, PPC, coping efficacy, and coping effectiveness.
The investigators anticipate to undertaking a parallel group, randomised controlled trial of 100 ITP patients. One part of the participants are randomly selected to receive hetrombopag with starting dose 5mg po qd for 8 weeks（increase daily dose to a maximum of 7.5 mg/day if platelet count\<50000 per μL following at least 2 weeks of treatment) combining with dexamethasone (given at a dose of 40 mg qd for 4 consecutive days). The others are selected to receive high-dose of dexamethasone alone. Patients who do not respond to dexamethasone may receive another cycle of high-dose dexamethasone therapy within 2 weeks. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. The purpose of this study is to report the efficacy and safety of Hetrombopag combining with high-dose dexamethasone therapy for the treatment of newly diagnosed ITP.
PURPOSE: A biji(soybean curd residue)-derived low molecular peptide extract is provided to suppress DPPH oxidation and collagenase expression, to promote procollagen generation, and to ensure excellent antioxidation, anti-wrinkling, and antiaging effects. CONSTITUTION: A cosmetic composition contains a biji(soybean curd residue)-derived low molecular peptide extract as an active ingredient. The molecular weight of the low molecular peptide is 500-3000 Da. The biji is prepared from one or more kinds selected from a group consisting of Glycine max (L.) Merr., Rhynchosia Nulubilis Loureiro, Phaseolus angularis (Willd.) W. Wight, Vigna radiata (L.) Wilczek, Vigna sinensis King, Pisum sativum L., Phaseolus vulgaris var. humilis, Viciafaba L., and Canavalia gladiata DC. A method for preparing the extract comprises: a step of adding an extraction solvent to the biji and extracting; a step of filtering the extract and performing a heat treatment; and a step of centrifuging. [Reference numerals] (AA) Intensity of light%; (BB) Mass/electric charge(m/z)
It is well documented that estrogens inhibit fluid intake. Most of this research, however, has focused on fluid intake in response to dipsogenic hormone and/or drug treatments in euhydrated rats. Additional research is needed to fully characterize the fluid intake effects of estradiol in response to true hypovolemia. As such, the goals of this series of experiments were to provide a detailed analysis of water intake in response to water deprivation in ovariectomized female rats treated with estradiol. In addition, these experiments also tested if activation of estrogen receptor alpha is sufficient to reduce water intake stimulated by water deprivation and tested for a role of glucagon like peptide-1 in the estrogenic control of water intake. As expected, estradiol reduced water intake in response to 24 and 48 h of water deprivation. The reduction in water intake was associated with a reduction in drinking burst number, with no change in drinking burst size. Pharmacological activation of estrogen receptor alpha reduced intake. Finally, estradiol-treatment caused a leftward shift in the behavioral dose response curve of exendin-4, the glucagon like peptide-1 agonist. While the highest dose of exendin-4 reduced 10 min intake in both oil and estradiol-treated rats, the intermediate dose only reduced intake in rats treated with estradiol. Together, this series of experiments extends previous research by providing a more thorough behavioral analysis of the anti-dipsogenic effect of estradiol in dehydrated rats, in addition to identifying the glucagon like peptide-1 system as a potential bioregulator involved in the underlying mechanisms by which estradiol reduces water intake in the female rat.
The subject invention provides methods for determining whether an agent is capable of either inhibiting or specifically inhibiting the fusion of a CD4<+> cell with an HIV-1 envelope glycoprotein<+> cell. The subject invention also provides a method for determining whether an agent is capable of specifically inhibiting the infection of a CD4<+> cell with HIV-1. This invention also provides an agent determined by the above-described methods. The subject invention further provides methods for quantitatively determining the ability of an antibody-containing sample to either inhibit or specifically inhibit the fusion of a CD4<+> cell with an HIV-1 envelope glycoprotein<+> cell. The subject invention further provides a method for determining the stage of an HIV-1 infection in an HIV-1-infected subject. The subject invention further provides a method for determining the efficacy of an anti-HIV-1 vaccination in a vaccinated, non-HIV-1-infected subject. The subject invention further provides kits for determining whether an agent is capable of either inhibiting or specifically inhibiting the fusion of a CD4<+> cell with an HIV-1 envelope glycoprotein<+> cell. The subject invention further provides a method for determining whether an HIV-1 isolate is syncytium-inducing. Finally, the subject invention provides a method for determining the stage of an HIV-1 infection in an HIV-1-infected subject.
The present invention relates to a novel medicinal composition with zaleplon, which comprises 0.1-to 10%(weight) of zaleplon and 1 to 40%(weight) of instant disintegrating agents foe water and acceptable additive agents of an oral cavity disintegrating preparation. The zaleplon the oral cavity disintegrating preparation of the zaleplon can be obtained after the zaleplon is made into the preparation in a composition mode. Stable and reliable, the present invention has the advantage of stability, reliability and good disintegrating degree and dissolution degree. The composition can obviously quicken the liberation velocity of the zaleplon, enhance the blood medicine level of a body, shorten peak time and display quick soporific effects via oral administration. The method of the present invention can be used for processing the spirit medicine of soporific, etc. via an optimum technique formulation, obtaining a stable and qualified preparation of quick release, quickening the absorption and the use of the medicine and quickly relieving the pain of patients. The present invention has a good application prospect; if the present invention can be popularized and applied, the present invention has good economical and social benefits.
Methods, systems, and devices for integrated photo-responsive contouring treatment are described. Methods include identifying a region of skin corresponding to a contouring treatment of the skin. The region of skin may be provided with a photo-responsive material overlying a portion of the region of the skin. Methods may include identifying one or more treatment regions overlapping the photo-responsive material. The treatment regions may be identified at least in part to apply the contouring treatment. Methods may include determining an irradiation profile for each of the one or more treatment regions to contour each respective treatment region as part of applying the contouring treatment. Methods may also include irradiating the photo-responsive material at the one or more treatment regions in accordance with the respective irradiation profiles. Irradiating the photo-responsive material may induce a localized change in shape of the photo-responsive material in the respective treatment regions.
Provided herein are methods for altering viral replication in a cell. The virus may be a member of the family Orthomyxoviridae, such as an influenza virus, or a member of the family Paramyxoviridae, such as human respiratory syncytial virus. Altering viral replication is accomplished through the use of polynucleotides. In one embodiment, a polynucleotide decreases expression of a polypeptide, such as a protease or a kinase. In one embodiment, a polynucleotide is an miRNA or an miRNA inhibitor. In some embodiments viral replication is decreased, and in other embodiments viral replication is increased. Also included are methods for treating a subject, and genetically modified cells having the characteristic of altered virus replication compared to a control cell.
BACKGROUND: There continues to be debate regarding the superiority of transcatheter (TAVR) over surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valves (BAV). We aimed to compare outcomes during readmissions in elderly patients with BAV who underwent SAVR or TAVR.
METHODS: Patients 65 years or older with BAV who underwent TAVR or isolated SAVR were identified using the National Readmission Database from 2012 through 2018. We compared outcomes during readmissions within 90 days after discharge from the index surgery. Propensity score matching was performed to adjust the baseline differences.
RESULTS: During the study period, 8555 and 1081 elderly patients with BAV underwent SAVR and TAVR, respectively. The number of patients who underwent TAVR went up by 179 % from 2012 to 2018. Propensity score matching yielded 573 patients in each group. A total of 111 (19.4 %) in the SAVR group and 125 (21.8 %) in the TAVR group were readmitted within 90 days after the index surgery (p = .31). The mortality during the readmissions within 90 days was equivalent between the two groups (0.9 % in the SAVR group vs. 3.2 % in the TAVR group, p = .22). However, the median hospital cost was approximately doubled in the TAVR group during the readmission (18,250 dollars vs. 9310 dollars in the SAVR group, p < .001).
CONCLUSIONS: Readmission within 90 days was common in both groups. While the mortality during the readmissions after the surgery was equivalent between the two groups, hospital cost was significantly more expensive in the TAVR group.
It is considered that the etiology of endometriosis is retrograde menstruation of endometrial tissue. Although shed endometrial cells are constantly exposed to a challenging environment with iron overload, oxidative stress and hypoxia, a few cells are able to survive and continue to proliferate and invade. Ferroptosis, an iron‑dependent form of non‑apoptotic cell death, is known to play a major role in the development and course of endometriosis. However, few papers have concentrated on the dynamic interaction between autophagy and ferroptosis throughout the progression of diseases. The present review summarized the current understanding of the mechanisms underlying autophagy and ferroptosis in endometriosis and discuss their role in disease development and progression. For the present narrative review electronic databases including PubMed and Google Scholar were searched for literature published up to the October 31, 2023. Autophagy and ferroptosis may be activated at early stages in endometriosis development. On the other hand, excessive activation of intrinsic pathways (e.g., estrogen and mechanistic target of rapamycin) may promote disease progression through autophagy inhibition. Furthermore, suppression of ferroptosis may cause further progression of endometriotic lesions. In conclusion, the autophagy and ferroptosis pathways may play a dual role in disease initiation and progression. The present review discussed the temporal transition of non‑apoptotic cell death regulation during disease progression from retrograde endometrium to early lesions to established lesions.